Free shipping on all orders over $ 500

MRX-2843

Cat. No. M10328
MRX-2843 Structure
Synonym:

UNC2371

Size Price Availability Quantity
1mg USD 60  USD60 In stock
5mg USD 170  USD170 In stock
10mg USD 280  USD280 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

MRX-2843 is a potent and orally active inhibitor of MERTK and FLT3 with IC50 values of 1.3 nM and 0.64 nM, respectively. MRX-2843 induces apoptosis and inhibits colony formation in AML cell lines. In MOLM-14 cells, treatment with MRX-2843 inhibits phosphorylation of FLT3 and downstream signaling through STAT5, ERK1/2 and AKT.

In vivo, MRX-2843 is 78% orally bioavailable at a dose of 3 mg/kg with a Cmax of 1.3 μM and a t1/2 of 4.4 hours. In MOLM-14 parental xenografts, both quizartinib and MRX-2843 increase median survival compare with that of vehicle-treated mice (172.5 days versus 40 days and 121 days versus 36 days, respectively, P<0.001).

Chemical Information
Molecular Weight 488.67
Formula C29H40N6O
CAS Number 1429882-07-4
Solubility (25°C) DMSO 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Yu-Ting Su, et al. Neurooncol Adv. MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment

[2] Alisa B Lee-Sherick, et al. JCI Insight. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity

[3] Dan Yan, et al. Clin Cancer Res. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members

[4] Katherine A Minson, et al. JCI Insight. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia

Related FLT3 Products
FLT3-IN-19

FLT3-IN-19 is a potent and selective FLT3 inhibitor with IC50 of 0.213 nM.

LT-540-717

LT-540-717 is a potent FLT3 inhibitor (IC50=0.62 nM) with antiproliferative activity.

GTP-14564

GTP-14564 is a tyrosine kinase inhibitor targeting to internal tandem duplication (ITD) and FLT3.

HDAC-IN-63

HDAC-IN-63 is a dual FLT3/HDAC inhibitor (IC50: 0.844 and 30.0 nM for FLT3 and HDAC1 respectively).

FLT3-IN-20

FLT3-IN-20 is a potent FLT3 inhibitor with IC50 values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: MRX-2843, UNC2371 supplier, FLT3, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.